Postmenopausal Osteoporosis: Clinical Trials

13 trials for Postmenopausal Osteoporosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 unknown, 1 recruiting. 13 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 10, Unknown 2, Recruiting 1
Phase 21Unknown 1

Follow Postmenopausal Osteoporosis: new trials by email Literature Review of Postmenopausal Osteoporosis trials Research Report on Postmenopausal Osteoporosis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
Blackcurrant (BC) extract, Placebo - Postmenopausal Osteoporosis, Gut Microbiome
Phase 1RecruitingUniversity of Connecticut1592026-07-012026-07-23
Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
HS-20090-2, Prolia - Postmenopausal Osteoporosis
Phase 1UnknownShanghai Hansoh Biomedical Co., Ltd1742021-07-262021-08-25
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk
blackcurrant (BC) extract - Postmenopausal Osteoporosis, Gut Microbiota
Phase 1CompletedUniversity of Connecticut512021-07-202025-08-12
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
SAL001, FORSTEO - Postmenopausal Osteoporosis
Phase 1CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.642020-08-192021-02-10
Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
Prolia®, CMAB807 - Postmenopausal Osteoporosis
Phase 1CompletedShanghai Biomabs Pharmaceutical Co., Ltd.1322019-07-012020-10-14
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
abaloparatide-sMTS - Postmenopausal Osteoporosis
Phase 1CompletedRadius Health, Inc.222019-04-092023-11-22
G56W1 in Women With Postmenopausal Osteoporosis
rhPTH(1-34) 28.2μg, rhPTH(1-34) 56.5μg, teriparatide acetate(Teribone™) - Postmenopausal Osteoporosis
Phase 1 / Phase 2UnknownShenzhen Salubris Pharmaceuticals Co., Ltd.1482018-10-012018-10-25
A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen
ZP-PTH, FORTEO - Postmenopausal Osteoporosis
Phase 1CompletedZosano Pharma Corporation242015-06-012016-08-23
The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
Denosumab, Midazolam - Postmenopausal Osteoporosis
Phase 1CompletedAmgen302010-11-012018-08-07
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
PTH134 - Postmenopausal Osteoporosis
Phase 1CompletedNovartis322008-05-012008-12-11
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
Oral salmon calcitonin, salmon calcitonin nasal spray - Postmenopausal Osteoporosis
Phase 1CompletedNovartis562006-10-012007-05-28
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg - Postmenopausal Osteoporosis, Postmenopause
Phase 1CompletedWyeth is now a wholly owned subsidiary of Pfizer2006-09-012007-06-11
Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
Oral salmon calcitonin - Postmenopausal Osteoporosis
Phase 1CompletedNovartis862006-08-012006-12-13

Narrower conditions

Osteoporosis, Postmenopausal (13)  ·  Osteoporosis (6)  ·  Cardiovascular Diseases (1)  ·  Hot Flashes (1)

Broader conditions

Bone Diseases (13)  ·  Bone Diseases, Metabolic (13)  ·  Metabolic Diseases (13)  ·  Musculoskeletal Diseases (13)  ·  Nutritional and Metabolic Diseases (13)  ·  Osteoporosis (7)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Denosumab (3)  ·  Teriparatide (2)  ·  salmon calcitonin (2)  ·  Midazolam (1)  ·  Parathyroid Hormone (1)

Sponsors

Novartis (3)  ·  Shenzhen Salubris Pharmaceuticals Co., Ltd. (2)  ·  University of Connecticut (2)  ·  Amgen (1)  ·  Radius Health, Inc. (1)  ·  Shanghai Biomabs Pharmaceutical Co., Ltd. (1)  ·  Shanghai Hansoh Biomedical Co., Ltd (1)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (1)  ·  Zosano Pharma Corporation (1)

Countries

China (4)  ·  United States (4)  ·  Denmark (2)  ·  Switzerland (1)

Top investigators

Dong Liu, PhD (1)  ·  Hugh Coleman, DO (1)  ·  Ock Chun, PhD (1)  ·  Ock K Chun, PhD (1)  ·  Weibo Xia, Prof. (1)  ·  Xiuhua Ren, Master (1)

Results publications

PMID 19055791, PMID 22289659, PMID 33638863, PMID 35140619, PMID 39019119

NIH funding

2025 (1)